AR083839A1 - Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos - Google Patents

Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos

Info

Publication number
AR083839A1
AR083839A1 ARP110104212A ARP110104212A AR083839A1 AR 083839 A1 AR083839 A1 AR 083839A1 AR P110104212 A ARP110104212 A AR P110104212A AR P110104212 A ARP110104212 A AR P110104212A AR 083839 A1 AR083839 A1 AR 083839A1
Authority
AR
Argentina
Prior art keywords
amino acid
seq
acid sequence
sequence
see seq
Prior art date
Application number
ARP110104212A
Other languages
English (en)
Inventor
Jay Gregory Calvert
Siao-Kun Wan Welch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR083839A1 publication Critical patent/AR083839A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10061—Methods of inactivation or attenuation
    • C12N2770/10062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10061—Methods of inactivation or attenuation
    • C12N2770/10064—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10071—Demonstrated in vivo effect

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Un virus aislado del Síndrome reproductivo y respiratorio porcino (PRRS), caracterizado porque la proteína de éste codificada por ORF1a se selecciona de un grupo que consiste en las secuencias de aminoácidos que contienen cualquiera de los siguientes: un aminoácido N en la secuencia de aminoácidos AMANVYD (SEQ ID Nº 9); un aminoácido N en la secuencia de aminoácidos IGHNAVM (SEQ ID Nº 12); un aminoácido D en la secuencia de aminoácidos TVPDGNC (SEQ ID Nº 15); un aminoácido Y en la secuencia de aminoácidos CWWYLFD (SEQ ID Nº 18); un aminoácido H en la secuencia de aminoácidos HGVHGKY (SEQ ID Nº 21); un aminoácido V en la secuencia de aminoácidos AAKVDQY (SEQ ID Nº 24); un aminoácido T en la secuencia de aminoácidos PSATDTS (SEQ ID Nº 27); un aminoácido L en la secuencia de aminoácidos LNSLLSK (SEQ ID Nº 30); un aminoácido C en la secuencia de aminoácidos APMCQDE (SEQ ID Nº 33); un aminoácido T en la secuencia de aminoácidos CAPTGMD (SEQ ID Nº 36); un aminoácido A en la secuencia de aminoácidos PKVAKVS (SEQ ID Nº 39); un aminoácido I en la secuencia de aminoácidos AGEIVGV (SEQ ID Nº 42); un aminoácido N en la secuencia de aminoácidos ADFNPEK (SEQ ID Nº 45); y un aminoácido I en la secuencia de aminoácidos QTPILGR (SEQ ID Nº 48).Reivindicación 13: Una molécula de polinucleótido aislada, caracterizada porque comprende una secuencia de ADN que codifica una molécula de ARN infecciosa que codifica un virus PRRS de los Estados Unidos, en donde dicha secuencia de ADN se selecciona del grupo que consiste en: (a) SEQ ID Nº 6; (b) una secuencia que tiene al menos 85 % de identidad con la secuencia de ADN de (a), en donde la proteína de este codificada por ORF1a tiene una secuencia de aminoácidos que contiene: (i) un aminoácido N en la secuencia de aminoácidos ANV (véase SEQ ID Nº 9); un aminoácido N en la secuencia de aminoácidos HNA (véase SEQ ID Nº 12); un aminoácido D en la secuencia de aminoácidos PDG (véase SEQ ID Nº 15), un aminoácido Y en la secuencia de aminoácidos WYL (véase SEQ ID Nº 18); un aminoácido H en la secuencia de aminoácidos VHG (véase SEQ ID Nº 21) o cualquier subconjunto de este; o (ii) un aminoácido V en la secuencia de aminoácidos KVD (véase SEQ ID Nº 24); un aminoácido T en la secuencia de aminoácidos ATD (véase SEQ ID Nº 27); un aminoácido L en la secuencia de aminoácidos SLL (véase SEQ ID Nº 30); un aminoácido C en la secuencia de aminoácidos MCQ (véase SEQ ID Nº 33) o cualquier subconjunto de este; o (iii) un aminoácido T en la secuencia de aminoácidos PTG (véase SEQ ID Nº 36); un aminoácido A en la secuencia de aminoácidos VAK (véase SEQ ID Nº 39) o cualquier subconjunto de este; o (iv) un aminoácido I en la secuencia de aminoácidos EIV (véase SEQ ID Nº 42); un aminoácido N en la secuencia de aminoácidos FNP (véase SEQ ID Nº 45); y aminoácido I en la secuencia de aminoácidos PIL (véase SEQ ID Nº 48) o cualquier subconjunto de este; y (c) una secuencia de ADN que se hibrida al complemento de una secuencia de ADN de (a) o (b) en condiciones muy rigurosas que comprenden hibridación de ADN unido al filtro en NaHPO4 0,5 M, 7% de SDS, 1 mM de EDTA a 65ºC y lavado en 0,1 de SSC/0,1% de SDS a 68ºC. Reivindicación 15: Una vacuna para proteger un animal porcino de la infección por un virus PRRS, caracterizada porque la vacuna comprende (a) un virus PRRS de los Estados Unidos genéticamente modificado, que es codificado por la molécula de polinucleótidos de acuerdo con la reivindicación 6, (b) dicha molécula infecciosa, (c) dicha molécula de polinucleótidos en forma de un plásmido, o (d) un vector viral que comprende la molécula de polinucleótidos, en donde el virus PRRS puede generar una respuesta inmunoprotectora eficaz contra la infección causada por el virus PRRS, en una cantidad eficaz para producir inmunoprotección contra la infección, y un portador adecuado para uso veterinario. Reivindicación 17: Un kit de diagnóstico caracterizado porque comprende moléculas de polinucleótidos que diferencian animales porcinos naturalmente infectados con una cepa de campo de un virus PRRS de animales porcinos vacunados con la vacuna de acuerdo con la reivindicación 15.
ARP110104212A 2010-11-10 2011-11-10 Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos AR083839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41200610P 2010-11-10 2010-11-10

Publications (1)

Publication Number Publication Date
AR083839A1 true AR083839A1 (es) 2013-03-27

Family

ID=45401109

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104212A AR083839A1 (es) 2010-11-10 2011-11-10 Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos

Country Status (20)

Country Link
US (4) US9566324B2 (es)
EP (1) EP2637688B1 (es)
JP (3) JP5793197B2 (es)
KR (1) KR101728202B1 (es)
CN (3) CN107974452B (es)
AR (1) AR083839A1 (es)
AU (1) AU2011327760B2 (es)
BR (1) BR112013011606A2 (es)
CA (1) CA2817486C (es)
DK (1) DK2637688T3 (es)
HK (1) HK1254832A1 (es)
HU (1) HUE031891T2 (es)
MX (1) MX350695B (es)
MY (1) MY173789A (es)
NZ (1) NZ610376A (es)
RU (1) RU2592667C2 (es)
TW (2) TWI458735B (es)
UA (1) UA108902C2 (es)
WO (1) WO2012063212A1 (es)
ZA (1) ZA201304204B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618797B2 (en) * 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
UA108902C2 (uk) * 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
JP6386999B2 (ja) 2012-05-17 2018-09-05 ゾエティス・エルエルシー ブタ生殖および呼吸症候群（ｐｒｒｓ）ウイルスに対する離乳前の効果的なワクチン接種
EP2874654B1 (en) * 2012-07-18 2018-11-28 South Dakota Board of Regents Novel arterivirus protein and expression mechanisms
US9457073B2 (en) 2012-09-26 2016-10-04 University Of Manitoba Live attenuated replication-competent arteriviruses having decreased dub/deisgylating activity
EP3119429A4 (en) 2014-03-21 2018-04-04 Nutech Ventures A non-naturally occuring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using
CN110072547B (zh) * 2016-12-14 2024-04-30 硕腾服务有限责任公司 断奶前对抗欧洲猪繁殖与呼吸综合征(prrs)病毒株的有效疫苗接种
JP7050446B2 (ja) 2017-09-25 2022-04-08 日本電産サンキョー株式会社 回転伝達機構およびダンパ装置
CN109468413B (zh) * 2018-12-14 2021-09-10 湖南中净生物科技有限公司 一种母猪繁殖障碍病原检测引物、试剂盒、病原检测方法和应用
CN111996213A (zh) * 2020-02-06 2020-11-27 广西大学 猪繁殖与呼吸综合征病毒双荧光标记基因重组毒株的构建方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3959457A (en) 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4205060A (en) 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5132117A (en) 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
HU218431B (hu) 1991-06-06 2000-08-28 Stichting Centraal Diergeneeskundig Instituut A rejtélyes sertésvészt okozó Lelystad-vírus, a vírusból származtatható polipeptidek, antigének és nukleinsavak és rejtélyes sertésvész elleni vakcinakészítmények
JPH0513188A (ja) 1991-06-28 1993-01-22 Toshiba Lighting & Technol Corp 放電灯点灯用電源回路
DK0601062T4 (da) 1991-08-26 2001-03-14 Univ Minnesota SIRS-vaccine og diagnosefremgangsmåde
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US20040087521A1 (en) 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
CA2187768A1 (en) 1994-04-15 1995-10-26 Moser, Charlotte A. Aqueous solvent encapsulation method, apparatus and microcapsules
DE69532369T3 (de) 1994-07-18 2010-11-04 Conzelmann, Karl-Klaus, Prof. Dr. Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
CA2196555C (en) 1994-08-05 2012-07-03 Michael P. Murtaugh Vr-2332 viral nucleotide sequence and methods of use
US6694021B1 (en) 1995-12-14 2004-02-17 Joseph G Julian Telephone handset sanitary guard
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
WO1998055626A2 (en) 1997-06-05 1998-12-10 Origen, Inc. Recombinant porcine reproductive and respiratory syndrome virus (prrsv) for use as a vaccine
US7691389B2 (en) * 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
NZ513289A (en) * 1998-12-22 2003-04-29 Pfizer Prod Inc Infectious cDNA clone of north american procine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7132106B2 (en) 1998-12-22 2006-11-07 Pfizer Inc. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7618797B2 (en) * 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
CN1406277A (zh) * 2000-01-26 2003-03-26 贝林格尔·英格海姆维特梅迪卡有限公司 Prrsv的重组减毒
BRPI0508928B1 (pt) * 2004-04-23 2015-10-06 Pah P & U Llc Processo de falicitação da infecção de uma célula de vertebrado por PRRSV e para medir a propensão de uma linhagem de células teste à referida infecção
KR101152012B1 (ko) * 2004-11-19 2012-07-04 인터벳 인터내셔널 비.브이. 돼지 생식기 및 호흡기 증후군 바이러스 균주 및 조성물
KR100996105B1 (ko) * 2005-02-25 2010-11-22 화이자 프로덕츠 인크. 돼지 생식기 호흡기 증후군 바이러스의 ｎ 단백질돌연변이체
UA95778C2 (ru) * 2005-06-24 2011-09-12 Риджентс Оф Зе Юниверсити Оф Миннесота Вирусы репродуктивно-респираторного синдрома свиней, их инфекционные клоны и мутанты и способы применения
BRPI0615610A2 (pt) * 2005-08-30 2011-05-24 Univ Nebraska processos e composições para vacinação de animais com antìgenos de prrsv com maior imunogenicidade
CN101848995A (zh) * 2007-06-25 2010-09-29 南达科他州立大学 重组的北美1型猪繁殖与呼吸综合征病毒及使用方法
CN101633909B (zh) * 2009-08-13 2012-05-09 华威特（北京）生物科技有限公司 预防猪感染猪繁殖与呼吸综合征的减毒活疫苗
UA108902C2 (uk) * 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
JP6386999B2 (ja) * 2012-05-17 2018-09-05 ゾエティス・エルエルシー ブタ生殖および呼吸症候群（ｐｒｒｓ）ウイルスに対する離乳前の効果的なワクチン接種

Also Published As

Publication number Publication date
US20200197507A1 (en) 2020-06-25
AU2011327760A1 (en) 2013-05-23
TW201518317A (zh) 2015-05-16
MX2013005205A (es) 2013-11-04
UA108902C2 (uk) 2015-06-25
CN107964546A (zh) 2018-04-27
EP2637688B1 (en) 2017-01-11
WO2012063212A1 (en) 2012-05-18
KR20130084692A (ko) 2013-07-25
CN107974452B (zh) 2021-08-13
MY173789A (en) 2020-02-21
RU2592667C2 (ru) 2016-07-27
US9566324B2 (en) 2017-02-14
MX350695B (es) 2017-09-13
US11351243B2 (en) 2022-06-07
US20220305110A1 (en) 2022-09-29
AU2011327760B2 (en) 2017-07-13
HUE031891T2 (en) 2017-08-28
US11904011B2 (en) 2024-02-20
CA2817486A1 (en) 2012-05-18
RU2013120979A (ru) 2014-12-20
US20140072589A1 (en) 2014-03-13
CN107964546B (zh) 2021-08-17
US20170136116A1 (en) 2017-05-18
EP2637688A1 (en) 2013-09-18
JP2017104121A (ja) 2017-06-15
TWI458735B (zh) 2014-11-01
JP2016019533A (ja) 2016-02-04
KR101728202B1 (ko) 2017-05-02
BR112013011606A2 (pt) 2021-05-25
JP5793197B2 (ja) 2015-10-14
HK1254832A1 (zh) 2019-07-26
DK2637688T3 (en) 2017-03-13
CN103517715A (zh) 2014-01-15
CA2817486C (en) 2019-07-23
TW201249864A (en) 2012-12-16
ZA201304204B (en) 2014-02-26
NZ610376A (en) 2015-05-29
CN107974452A (zh) 2018-05-01
JP2014500721A (ja) 2014-01-16

Similar Documents

Publication Publication Date Title
AR083839A1 (es) Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos
HRP20180282T1 (hr) Imunoterapija na bazi indoleamin 2, 3-dioksigenaze
HRP20191594T1 (hr) Poticanje imunosnog odgovora
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
AR101421A1 (es) Cepas de paenibacillus antifúngicas, compuestos de tipo fusaricidin y sus usos
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
CO6290791A2 (es) Vacunas y composiciones inmunogénicas que contienen nuevas cepas del circo virus porcino tipo 2b para inmunizar cerdos contra pmws
PE20210668A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
RU2018123480A (ru) Вакцина против кошачьего калицивируса
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
NZ723229A (en) Immunogens for hiv vaccination
PE20090683A1 (es) Peptidos de senalizacion
JP2018537996A5 (es)
CO6362047A2 (es) Virus sincitial respiratorio vivo atenuado
JP2012515557A5 (es)
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
RU2019117647A (ru) Эффективная вакцинация против европейских штаммов вируса репродуктивного и респираторного синдрома (prrs) до отлучения от матери
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
JP2019505567A5 (es)
AR083533A1 (es) Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR088216A1 (es) Agentes para el control de la avispa de las agallas
RU2013102413A (ru) Парапоксвирусные векторы
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
PE20121171A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos

Legal Events

Date Code Title Description
FG Grant, registration